MX384378B - Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca. - Google Patents

Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca.

Info

Publication number
MX384378B
MX384378B MX2015001826A MX2015001826A MX384378B MX 384378 B MX384378 B MX 384378B MX 2015001826 A MX2015001826 A MX 2015001826A MX 2015001826 A MX2015001826 A MX 2015001826A MX 384378 B MX384378 B MX 384378B
Authority
MX
Mexico
Prior art keywords
treatment
heart failure
subsecence
neuroregulin
prophylaxis
Prior art date
Application number
MX2015001826A
Other languages
English (en)
Spanish (es)
Inventor
Anthony Caggiano
Anindita Ganguly
Jennifer Iaci
Tom Parry
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of MX384378B publication Critical patent/MX384378B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2015001826A 2008-07-17 2009-07-17 Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca. MX384378B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13517108P 2008-07-17 2008-07-17
PCT/US2009/004130 WO2010030317A2 (en) 2008-07-17 2009-07-17 Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure

Publications (1)

Publication Number Publication Date
MX384378B true MX384378B (es) 2025-03-14

Family

ID=42005671

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015001826A MX384378B (es) 2008-07-17 2009-07-17 Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca.
MX2011000696A MX2011000696A (es) 2008-07-17 2009-07-17 Dosificacion terapeutica de una neurregulina o una subsecuencia de la misma para el tratamiento o la profilaxis de insuficiencia cardiaca.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2011000696A MX2011000696A (es) 2008-07-17 2009-07-17 Dosificacion terapeutica de una neurregulina o una subsecuencia de la misma para el tratamiento o la profilaxis de insuficiencia cardiaca.

Country Status (13)

Country Link
US (5) US20110166068A1 (enExample)
EP (3) EP3338791B1 (enExample)
JP (5) JP5797112B2 (enExample)
CN (3) CN107019794B (enExample)
AU (3) AU2009292216B2 (enExample)
BR (1) BRPI0916442A2 (enExample)
CA (1) CA2731113A1 (enExample)
DK (2) DK2320933T3 (enExample)
ES (2) ES2664394T3 (enExample)
MX (2) MX384378B (enExample)
PL (2) PL2320933T3 (enExample)
RU (4) RU2536938C2 (enExample)
WO (1) WO2010030317A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX384378B (es) 2008-07-17 2025-03-14 Acorda Therapeutics Inc Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca.
WO2010019275A2 (en) 2008-08-15 2010-02-18 Acorda Therapeutics, Inc. Compositions and methods for treatment during non-acute periods following cns neurological injury
JP5743898B2 (ja) * 2008-11-28 2015-07-01 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
MX2012004386A (es) 2009-10-14 2012-05-23 Acorda Therapeutics Inc Uso de una neurregulina para tratar la lesion del nervio periferico.
WO2013053076A1 (en) * 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
ES2857810T3 (es) * 2012-03-30 2021-09-29 Acorda Therapeutics Inc Uso de GGF2 para tratar el dolor neuropático luego de lesión del nervio periférico
CA2904055A1 (en) * 2013-03-06 2014-09-12 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
JP6568052B2 (ja) 2013-05-22 2019-09-04 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． 心不全を治療するためのニューレグリンの徐放
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
JP7181084B2 (ja) 2015-09-25 2022-11-30 ダグラス ビー． ソーヤー， 心臓傷害を処置するための方法
EP3445386B1 (en) * 2016-04-19 2020-08-26 Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI) Neuregulin for the treatment and/or prevention of tumors of the nervous system
CN110835368A (zh) * 2018-08-15 2020-02-25 上海泽生科技开发股份有限公司 神经调节蛋白多肽片段及其用途
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
CA3157354A1 (en) * 2019-09-16 2021-03-25 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant human neuregulin derivatives and use thereof
WO2023070078A1 (en) * 2021-10-22 2023-04-27 The Research Institute At Nationwide Children's Hospital Neuregulin for protection against respiratory viral infection and post-viral disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115554B1 (en) * 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US6087323A (en) 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
US6051401A (en) 1998-07-28 2000-04-18 Bayer Corporation Methods and constructs for protein expression
BR9914051A (pt) 1998-09-25 2001-06-19 Cubist Pharm Inc Métodos para administração de antibióticos
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) * 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
CA2388918A1 (en) 1999-11-12 2001-05-17 Entremed, Inc. Methods for administration of therapeutic agents on an antiangiogenic schedule
MXPA02011656A (es) 2000-05-23 2004-07-30 Cenes Pharmaceuticals Inc Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
EP1569689A4 (en) 2002-01-18 2009-08-05 Novartis Vaccines & Diagnostic IL2 / ANTI-HER2-ANTIBODY COMBINATION THERAPY AGAINST CANCER, which is characterized by overexpression of the HER2-RECEPTOR PROTEIN
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
WO2006087419A2 (en) * 2005-02-18 2006-08-24 Orion Corporation A method for administering levosimendan
BRPI0609427A2 (pt) 2005-03-23 2010-04-06 Pfizer Prod Inc composição farmacêutica para o tratamento de cáncer de próstata e uso de um agente de terapia hormonal e de um anticorpo, ou uma porção de ligação a antìgeno do mesmo
WO2007028085A2 (en) 2005-09-02 2007-03-08 Morehouse School Of Medicine Neuregulin for prevention and treatment of damage from acute assault on vascular and neuronal tissues
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
BRPI0620819A2 (pt) * 2005-12-30 2011-11-22 Zensun Shangai Science & Technology Ltd uso de uma neuregulina (nrg) de liberação prolongada, nrg em uma liberação prolongada de uma dosagem baixa constante, e, composição de liberação prolongada para prevenir, tratar ou retardar uma doença ou distúrbio em um mamìfero
US8410050B2 (en) 2008-02-29 2013-04-02 Acorda Therapeutics, Inc. Method for achieving desired glial growth factor 2 plasma levels
MX384378B (es) 2008-07-17 2025-03-14 Acorda Therapeutics Inc Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca.
MX2012004386A (es) 2009-10-14 2012-05-23 Acorda Therapeutics Inc Uso de una neurregulina para tratar la lesion del nervio periferico.
EP2603221A4 (en) 2010-08-13 2014-02-26 Univ Georgetown GGF2 AND METHOD FOR ITS APPLICATION
ES2857810T3 (es) 2012-03-30 2021-09-29 Acorda Therapeutics Inc Uso de GGF2 para tratar el dolor neuropático luego de lesión del nervio periférico

Also Published As

Publication number Publication date
JP2017200949A (ja) 2017-11-09
JP2015129137A (ja) 2015-07-16
US20180280477A1 (en) 2018-10-04
JP6189879B2 (ja) 2017-08-30
RU2020111236A3 (enExample) 2021-09-21
BRPI0916442A2 (pt) 2018-06-19
RU2536938C2 (ru) 2014-12-27
US9198951B2 (en) 2015-12-01
US20200009228A1 (en) 2020-01-09
JP2011528353A (ja) 2011-11-17
AU2009292216B2 (en) 2015-03-05
WO2010030317A2 (en) 2010-03-18
US11235031B2 (en) 2022-02-01
EP2320933A4 (en) 2013-02-27
RU2011105821A (ru) 2012-08-27
DK2320933T3 (en) 2018-04-16
CN107019794B (zh) 2021-03-12
CN104623633A (zh) 2015-05-20
CN102159236A (zh) 2011-08-17
DK3338791T3 (da) 2019-12-16
CN107019794A (zh) 2017-08-08
RU2014141514A (ru) 2016-05-10
ES2763184T3 (es) 2020-05-27
JP2022023208A (ja) 2022-02-07
CA2731113A1 (en) 2010-03-18
EP2320933A1 (en) 2011-05-18
HK1256637A1 (en) 2019-09-27
ES2664394T3 (es) 2018-04-19
EP3338791A1 (en) 2018-06-27
JP5797112B2 (ja) 2015-10-21
US9956266B2 (en) 2018-05-01
US20160113999A1 (en) 2016-04-28
AU2015202877B2 (en) 2017-03-09
AU2017203528A1 (en) 2017-06-15
MX2011000696A (es) 2011-07-29
US20110166068A1 (en) 2011-07-07
AU2009292216A1 (en) 2010-03-18
RU2719199C1 (ru) 2020-04-17
EP2320933B1 (en) 2017-12-27
RU2698090C2 (ru) 2019-08-22
RU2020111236A (ru) 2021-09-21
US20130324466A1 (en) 2013-12-05
AU2015202877A1 (en) 2015-06-18
JP2019196370A (ja) 2019-11-14
EP3632459A1 (en) 2020-04-08
PL3338791T3 (pl) 2020-04-30
EP3338791B1 (en) 2019-09-18
PL2320933T3 (pl) 2018-07-31

Similar Documents

Publication Publication Date Title
MX384378B (es) Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca.
EA201490521A1 (ru) Варианты фактора роста фибробластов 21
CO6382125A2 (es) Inhibidores de proteína quinasa
EA201492053A1 (ru) Белки фактора роста фибробластов 21
EA201490254A1 (ru) Комбинированное лечение гепатита с
CR20130234A (es) Métodos de tratamiento de trastornos asociados con el fgf21
EA201492064A1 (ru) Варианты фактора роста фибробластов 21
MX350046B (es) Tratamientos para trastornos gastrointestinales.
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
CL2008002411A1 (es) Compuestos derivados de heterociclos de nitrogenos;composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la miosina del musculo liso o la miosina no muscular, tales como hipertension, enfermedad pulmonar, glaucoma, apoplejia, enfermedades broncocontrictoras, entre otras.
CR20170320A (es) Mezcla de ácidos carboxílicos para tratar pacientes con insuficiencia renal
ECSP077340A (es) Nuevos derivados de pirimidina y su uso como moduladores del ppar-alfa
EA201291167A1 (ru) Замещенные гетероциклилбензилпиразолы и их применение
AR109799A1 (es) Composición para el tratamiento del cabello
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
EA201500061A1 (ru) Фармацевтическая композиция для терапии легочной формы высотной болезни, вызванной кислородным голоданием и пониженным атмосферным давлением
PH12013500559A1 (en) Combination therapy for treating hcv infection
CY1115961T1 (el) Ανυδρη μορφη κρυσταλλικης μηλεϊνικης ορβεπιταντης (orvepitant maleate)
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
MX2020007462A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
DOP2010000156A (es) Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca
EA201200754A1 (ru) Традиционное китайское лекарственное средство, содержащее экстракты дан-шен (danshen) и сан-ки (sanqi), и его применение
MX380927B (es) Promotor de absorcion gi superior amortiguado.
BR112015013223A2 (pt) composição farmacêutica